Stability of infliximab dosing in inflammatory bowel disease: results from a multicenter US chart review
Authors:
- 1 January 2011
- journal article
- research article
- Published by Informa Healthcare in Journal of Medical Economics
- Vol. 14 (4) , 397-402
Abstract
Objective:Infliximab dosing for inflammatory bowel disease (IBD) is based on patient weight and treatment response. Understanding dosing patterns may provide insight into treatment response and predictability of treatment cost. The purpose of this medical record review was to assess dose and dose frequency of infliximab maintenance treatment in patients with IBD using patient chart data.Methods:A retrospective chart review was conducted at 14 community gastroenterology clinics (GI clinics). Patients were aged ≥18 years, diagnosed with Crohn’s disease (CD) or ulcerative colitis (UC), and had a first infliximab administration (index date) between January 1, 2005 and September 30, 2007. At least 24 months of continuous data availability were required with dosing data collected for 12 months after initiation of infliximab therapy. Patients with biologic use and/or participation in an IBD clinical trial within 12 months before the index date were excluded.Results:Charts from 182 CD patients and 86 UC p...Keywords
This publication has 24 references indexed in Scilit:
- Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters CommitteeAmerican Journal of Gastroenterology, 2010
- Medical Management of Crohn’s Disease: Treatment Algorithms 2009Digestive Diseases, 2009
- Evidence of Endothelial Dysfunction in Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2009
- Management of Crohn's Disease in AdultsAmerican Journal of Gastroenterology, 2009
- Infliximab to treat severe ulcerative colitisWorld Journal of Gastroenterology, 2009
- Meta‐analysis: mortality in Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2007
- Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT RegistryClinical Gastroenterology and Hepatology, 2006
- Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunitiesInflammatory Bowel Diseases, 2006
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Annual cost of care for Crohn's disease: a payor perspectiveAmerican Journal of Gastroenterology, 2000